Effects of peripheral administration of synthetic human glucose‐dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
- 6 July 2009
- journal article
- clinical trial
- Published by Wiley in Clinical Endocrinology
- Vol. 71 (2) , 195-201
Abstract
Summary: Background Apart from their role in insulin secretion and glucose homeostasis, the incretin hormones glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic peptide (GIP) exert a number of extra‐pancreatic effects which in the case of GIP remain largely unknown.Design/patients Six obese male patients with diet‐controlled type 2 diabetes (T2DM) and six healthy lean male subjects were studied. The protocol included four experiments for each participant that were carried out in randomized order and included: GLP‐1 infusion at a rate of 1 pmol/kg/min for 4 h, GIP at a rate of 2 pmol/kg/min, GLP‐1 (at 1 pmol/kg/min) with GIP (at 2 pmol/kg/min), and placebo infusion for 4 h. Energy expenditure (EE) was measured throughout with indirect calorimetry and subjects were given a series of visual analogue scales to rate hourly their hunger, fullness, urge to eat and prospective consumption of food. Immediately following termination of the infusions all subjects were offered a free choice buffet lunch and total calorie and macronutrient intake was calculated.Results During GIP infusion there was a trend for healthy subjects to report higher hunger scores and a reduction in EE only when compared with placebo. These parameters remained unchanged in patients with T2DM. Ad libitum energy intake after all four infusions was the same in both groups.Conclusion We report here for the first time that GIP infusion may impact on resting EE and subjective appetite sensations in normal weight healthy subjects and further studies with larger numbers of subjects are required to help define more conclusively the precise role of GIP in energy balance in humans.Keywords
This publication has 29 references indexed in Scilit:
- Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditureJournal of Clinical Investigation, 2007
- Physiology of GIP - A Lesson from GIP Receptor Knockout MiceHormone and Metabolic Research, 2004
- Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humansAmerican Journal of Physiology-Endocrinology and Metabolism, 2004
- A Meta-Analysis of the Effect of Glucagon-Like Peptide-1 (7-36) Amide on Ad Libitum Energy Intake in HumansThe Journal of Clinical Endocrinology & Metabolism, 2001
- The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesityInternational Journal of Obesity, 2001
- Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.International Journal of Obesity, 1999
- Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans.Journal of Clinical Investigation, 1998
- Effects of glucagon‐like peptide 1 (7–36 amide) on whole‐body protein metabolism in healthy manEuropean Journal of Clinical Investigation, 1997
- A role for glucagon-like peptide-1 in the central regulation of feedingNature, 1996
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993